Top

Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

Category : Diagnostic and Biotech  | Published Date : Aug-2015 | Pages : 84
enquire GET DISCOUNT

About Chronic Lymphocytic Leukemia 
Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).

Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

Covered in this Report
In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia. 

Based on the type of molecule, we group the market into two categories:
• Biologics
• Small molecules

Based on the route of administration, we group the market into two:
• Oral
• Parenteral

This report includes a discussion of the market in the following three regions: 
• Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle

Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE

• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is a major untapped market with many leading vendors in the global chronic lymphocytic leukemia therapeutics market. 

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers and challenges, as well as the key trends.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• F. Hoffmann-La Roche
• Novartis 
• Teva Pharmaceutical Industries

Other Prominent Vendors
• Actavis 
• Amgen
• Aryogen 
• Astellas
• Bristol-Myers Squibb
• Eagle Pharmaceuticals 
• Eisai
• Fresenius Kabi
• Genmab
• Gilead Sciences
• H. Lundbeck
• Hospira 
• idd biotech 
• Immunomedics 
• Johnson & Johnson
• Mundipharma
• Mylan
• Noxxon 
• Ono Pharmaceutical
• PDL BioPharma
• Pfizer
• Pharmacyclics
• Regeneron
• Sagent Pharmaceutical
• Sanofi
• SymBio Pharmaceuticals
• TheraMAB 

Key Market Driver
• Increase in Patient Pool
• For a full, detailed list, view our report

Key Market Challenge
• Unknown Disease Etiology
• For a full, detailed list, view our report

Key Market Trend
• Strategic Alliances
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Gazyva/Gazyvaro

04.1.2 MabThera/Rituxan

04.1.3 Arzerra

04.1.4 Treanda

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Disease Overview

06.1 Understanding the Disease

06.2 Types of Chronic Lymphocytic Leukemia

06.3 Symptoms

06.4 Diagnosis

06.5 Staging

06.6 Epidemiology

06.7 Management

06.8 Economic Burden

07. Introduction

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 Five Forces Analysis

09. Pipeline Portfolio

09.1 Key Information on the Major Pipeline Molecules

09.1.1 RG 105 SC Formulation

09.1.2 Obinutuzumab/ Venetoclax

09.1.3 RG 7596 (Polatuzumab vedotin)

09.1.4 RG 7601 (Venetoclax)

10. Market Segmentation by Route of Administration

10.1 Oral

10.2 Parenteral

11. Market Segmentation by Type of Molecule

11.1 Small Molecules

11.2 Biologics

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2014

20.2.1 F. Hoffmann-La Roche

20.2.2 Teva Pharmaceutical Industries

20.2.3 Novartis

20.3 Other and Future Prominent Vendors

21. Key Vendor Analysis

21.1 F. Hoffmann-La Roche

21.1.1 Key Facts

21.1.2 Business Overview

21.1.3 Business Segmentation

21.1.4 Business Segmentation by Revenue 2012 and 2013

21.1.5 Sales by Geography

21.1.6 Business Strategy

21.1.7 Key Information

21.1.8 SWOT Analysis

21.2 Novartis

21.2.1 Key Facts

21.2.2 Business Description

21.2.3 Business Segmentation

21.2.4 Revenue by Business Segmentation

21.2.5 Revenue Comparison 2012 and 2013

21.2.6 Sales by Geography

21.2.7 Business Strategy

21.2.8 Key Developments

21.2.9 SWOT Analysis

21.3 Teva Pharmaceutical Industries

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Business Segmentation

21.3.4 Revenue by Business Segmentation

21.3.5 Revenue Comparison 2012 and 2013

21.3.6 Revenue Segmentation by Geography

21.3.7 Business Strategy

21.3.8 Key Developments

21.3.9 SWOT Analysis

22. Other Reports in this Series

List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Chronic Lymphocytic Leukemia
Exhibit 3: Type of Chronic Lymphocytic Leukemia
Exhibit 4: Major Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 5: Other Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 6: Rai Staging of Chronic Lymphocytic Leukemia
Exhibit 7: Binet Staging of Chronic Lymphocytic Leukemia
Exhibit 8: Management of Chronic Lymphocytic Leukemia
Exhibit 9: Economic Burden of Chronic Lymphocytic Leukemia
Exhibit 10: Global Chronic Lymphocytic Leukemia Therapeutics Market 2014-2019 ($ millions)
Exhibit 11: Key Takeaways: Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 12: Drug Candidates by Stage of Development, in percentage
Exhibit 13: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Route of Administration
Exhibit 14: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Type of Molecules
Exhibit 15: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Geography, 2014
Exhibit 16: Drivers of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 17: Challenges of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 18: Trends of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 19: Global Sales and YoY Growth Rate of Rituxan/MabThera 2010-2014 ($ millions)
Exhibit 20: Global Sales and YoY Growth Rate of Treanda 2010-2014 ($ millions)
Exhibit 21: Global Sales and YoY Growth Rate of Arzerra 2010-2014($ millions)
Exhibit 22: Sales and YoY Growth Rate of Arzerra in US 2010-2014 ($ millions)
Exhibit 23: Sales and YoY Growth Rate of Arzerra in Europe 2010-2014 ($ millions)
Exhibit 24: Region-wise Revenue Comparison of Arzerra 2010-2014 ($ millions)
Exhibit 25: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 26: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 27: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 28: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 29: Novartis AG: Business Segmentation
Exhibit 30: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 31: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 32: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 33: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 34: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
Exhibit 35: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 36: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 2500
Five User: US $ 3000
Site User: US $ 4000
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top